Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: Pooled analysis of data from four phase 3 clinical trials

Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644 Huang, 2009, A comprehensive definition for metabolic syndrome, Dis. Model. Mech., 2, 231, 10.1242/dmm.001180 Nahmias, 2020, Glycemia and atherosclerotic cardiovascular disease: exploring the gap between risk marker and risk factor, Front. Cardiovasc. Med., 7, 10.3389/fcvm.2020.00100 Hansen, 2017, Bile acid sequestrants for glycemic control in patients with type 2 diabetes: a systematic review with meta-analysis of randomized controlled trials, J. Diabet. Complicat., 31, 918, 10.1016/j.jdiacomp.2017.01.011 Simental-Mendía, 2018, Effect of fibrates on glycemic parameters: a systematic review and meta-analysis of randomized placebo-controlled trials, Pharmacol. Res., 132, 232, 10.1016/j.phrs.2017.12.030 Grundy, 2018, AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines, J. Am. Coll. Cardiol., 73, e285, 10.1016/j.jacc.2018.11.003 Sattar, 2010, Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials, Lancet, 375, 735, 10.1016/S0140-6736(09)61965-6 Preiss, 2011, Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis, JAMA, 305, 2556, 10.1001/jama.2011.860 Abbasi, 2021, Statins are associated with increased insulin resistance and secretion, Arterioscler. Thromb. Vasc. Biol., 41, 2786, 10.1161/ATVBAHA.121.316159 Angelidi, 2018, Is atorvastatin associated with new onset diabetes or deterioration of glycemic control? Systematic review using data from 1.9 million patients, Internet J. Endocrinol., 2018 Liew, 2014, Statins use is associated with poorer glycaemic control in a cohort of hypertensive patients with diabetes and without diabetes, Diabetol. Metab. Syndrome, 6, 53, 10.1186/1758-5996-6-53 Goldberg, 2008, Effects of niacin on glucose control in patients with dyslipidemia, Mayo Clin. Proc., 83, 470, 10.4065/83.4.470 Goldie, 2016, Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials, Heart, 102, 198, 10.1136/heartjnl-2015-308055 Henry, 2018, Effect of alirocumab on lipids and lipoproteins in individuals with metabolic syndrome without diabetes: pooled data from 10 phase 3 trials, Diabetes Obes. Metabol., 20, 1632, 10.1111/dom.13273 Deedwania, 2021, Efficacy and safety of PCSK9 inhibition with evolocumab in reducing cardiovascular events in patients with metabolic syndrome receiving statin therapy: secondary analysis from the Fourier randomized clinical trial, JAMA Cardiol., 6, 139, 10.1001/jamacardio.2020.3151 Leiter, 2019, Inclisiran lowers LDL-C and PCSK9 irrespective of diabetes status: the ORION-1 randomized clinical trial, Diabetes Care, 42, 173, 10.2337/dc18-1491 Colhoun, 2016, No effect of PCSK9 inhibitor alirocumab on the incidence of diabetes in a pooled analysis from 10 ODYSSEY phase 3 studies, Eur. Heart J., 37, 2981, 10.1093/eurheartj/ehw292 Ray, 2020, Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol, N. Engl. J. Med., 382, 1507, 10.1056/NEJMoa1912387 Ballantyne, 2018, Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study, Atherosclerosis, 277, 195, 10.1016/j.atherosclerosis.2018.06.002 Goldberg, 2019, Effect of bempedoic acid vs placebo added to maximally tolerated statins on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial, JAMA, 322, 1780, 10.1001/jama.2019.16585 Laufs, 2019, Efficacy and safety of bempedoic acid in patients with hypercholesterolemia and statin intolerance, J. Am. Heart Assoc., 8, 10.1161/JAHA.118.011662 Ray, 2019, Safety and efficacy of bempedoic acid to reduce LDL cholesterol, N. Engl. J. Med., 380, 1022, 10.1056/NEJMoa1803917 Nissen, 2023, Bempedoic acid and cardiovascular outcomes in statin-intolerant patients, N. Engl. J. Med., 388, 1353, 10.1056/NEJMoa2215024 Banach, 2020, Association of bempedoic acid administration with atherogenic lipid levels in phase 3 randomized clinical trials of patients with hypercholesterolemia, JAMA Cardiol., 5, 1124, 10.1001/jamacardio.2020.2314 Leiter, 2022, Bempedoic acid in patients with type 2 diabetes mellitus, prediabetes, and normoglycaemia: a post hoc analysis of efficacy and glycaemic control using pooled data from phase 3 clinical trials, Diabetes Obes. Metabol., 24, 868, 10.1111/dom.14645 Friedewald, 1972, Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge, Clin. Chem., 18, 499, 10.1093/clinchem/18.6.499 Cicero, 2020, Lipid, et al. Efficacy and safety of bempedoic acid for the treatment of hypercholesterolemia: a systematic review and meta-analysis, PLoS Med., 17, 10.1371/journal.pmed.1003121 Kim, 2016, Effect of fixed-dose combinations of ezetimibe plus rosuvastatin in patients with primary hypercholesterolemia: MRS-ROZE (Multicenter Randomized Study of ROsuvastatin and eZEtimibe), Cardiovasc. Ther., 34, 371, 10.1111/1755-5922.12213 den Engelsen, 2012, High-sensitivity C-reactive protein to detect metabolic syndrome in a centrally obese population: a cross-sectional analysis, Cardiovasc. Diabetol., 11, 25, 10.1186/1475-2840-11-25 Ndumele, 2006, Interrelationships between inflammation, C-reactive protein, and insulin resistance, J. Cardiometab. Syndr., 1, 190, 10.1111/j.1559-4564.2006.05538.x